Northwest Biotherapeutics Overview

  • Year Founded
  • 1996

Year Founded

  • Status
  • Public

  • Employees
  • 25

Employees

  • Stock Symbol
  • NWBO

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.28
  • (As of Friday Closing)

Northwest Biotherapeutics General Information

Description

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.

Contact Information

Website
www.nwbio.com
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 4800 Montgomery Lane
  • Suite 800
  • Bethesda, MD 20814
  • United States
+1 (240)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
PINX
Vertical(s)
Corporate Office
  • 4800 Montgomery Lane
  • Suite 800
  • Bethesda, MD 20814
  • United States
+1 (240)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Northwest Biotherapeutics Stock Performance

As of 13-Jun-2025, Northwest Biotherapeutics’s stock price is $0.28. Its current market cap is $400M with 1.44B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.28 $0.26 $0.17 - $0.50 $400M 1.44B 3.85M -$0.07

Northwest Biotherapeutics Financials Summary

As of 31-Mar-2025, Northwest Biotherapeutics has a trailing 12-month revenue of $1.47M.

In Thousands,
USD
TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 398,420 433,391 867,856 860,860
Revenue 1,473 1,382 1,932 1,683
EBITDA (74,921) (73,967) (55,625) (97,464)
Net Income (84,809) (83,778) (62,599) (105,032)
Total Assets 27,505 26,728 27,865 31,323
Total Debt 69,005 67,440 45,560 26,253
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Northwest Biotherapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Northwest Biotherapeutics‘s full profile, request access.

Request a free trial

Northwest Biotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a
Drug Discovery
Bethesda, MD
25 As of 2024

Cambridge, MA
 

Waltham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Northwest Biotherapeutics Competitors (55)

One of Northwest Biotherapeutics’s 55 competitors is Aura Biosciences, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Formerly VC-backed Cambridge, MA
Apellis Pharmaceuticals Formerly VC-backed Waltham, MA
Oncorus Formerly VC-backed Andover, MA
Advanced Proteome Therapeutics Corporation Boston, MA
Sagimet Biosciences Formerly VC-backed San Mateo, CA
You’re viewing 5 of 55 competitors. Get the full list »

Northwest Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Northwest Biotherapeutics Acquisitions (2)

Northwest Biotherapeutics’s most recent deal was a Merger/Acquisition with Flaskworks for . The deal was made on 28-Aug-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Flaskworks 28-Aug-2020 Merger/Acquisition Other Devices and Supplies
MithraGen 01-Jan-2008 Merger/Acquisition Biotechnology
To view Northwest Biotherapeutics’s complete acquisitions history, request access »

Northwest Biotherapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Northwest Biotherapeutics’s complete esg history, request access »

Northwest Biotherapeutics FAQs

  • When was Northwest Biotherapeutics founded?

    Northwest Biotherapeutics was founded in 1996.

  • Where is Northwest Biotherapeutics headquartered?

    Northwest Biotherapeutics is headquartered in Bethesda, MD.

  • What is the size of Northwest Biotherapeutics?

    Northwest Biotherapeutics has 25 total employees.

  • What industry is Northwest Biotherapeutics in?

    Northwest Biotherapeutics’s primary industry is Drug Discovery.

  • Is Northwest Biotherapeutics a private or public company?

    Northwest Biotherapeutics is a Public company.

  • What is Northwest Biotherapeutics’s stock symbol?

    The ticker symbol for Northwest Biotherapeutics is NWBO.

  • What is the current stock price of Northwest Biotherapeutics?

    As of 13-Jun-2025 the stock price of Northwest Biotherapeutics is $0.28.

  • What is the current market cap of Northwest Biotherapeutics?

    The current market capitalization of Northwest Biotherapeutics is $400M.

  • What is Northwest Biotherapeutics’s current revenue?

    The trailing twelve month revenue for Northwest Biotherapeutics is $1.47M.

  • Who are Northwest Biotherapeutics’s competitors?

    Aura Biosciences, Apellis Pharmaceuticals, Oncorus, Advanced Proteome Therapeutics, and Sagimet Biosciences are some of the 55 competitors of Northwest Biotherapeutics.

  • What is Northwest Biotherapeutics’s annual earnings per share (EPS)?

    Northwest Biotherapeutics’s EPS for 12 months was -$0.07.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »